Table 2.
Sociodemographic Variables for the 20% of Placebo Patients Whose PSAS Total Score Had the Greatest Improvement or Decrement at Discharge When Compared with Baseline (Restricted to Patients with One Placebo Phase Who Were Taking Typical Antipsychotic Medications at Discharge (Analysis 1))
| Improved (n = 13) | Worsened (n = 13) | t | p≤ | Mean difference | 95% CI
|
||
|---|---|---|---|---|---|---|---|
| Lower | Upper | ||||||
| Age (years) at admission (SD) | 30.1 (7.9) | 32.8 (9.4) | 0.83 | 0.50 | 2.81 | −9.84 | 4.22 |
| Duration (years) of illness (SD) | 11.9 (7.2) | 12.5 (10.1) | 0.17 | 0.87 | −0.58 | −7.70 | 6.53 |
| Years of education (SD) | 12.2 (2.4) | 12.8 (1.9) | 0.71 | 0.48 | 0.60 | −2.41 | 1.17 |
| Gender (F/M) | 5/8 | 4/9 | 0.99b | ||||
| Race (white/nonwhite) | 10/3 | 13/0 | 0.22b | ||||
| Married (yes/no) | 1/12 | 4/9 | 0.32b | ||||
| Tardive dyskinesia (yes/no) | 6/7 | 4/9 | 0.69b | ||||
| Smoker (yes/no) | 10/3 | 10/3 | 0.99b | ||||
| Verbal IQ (SD) | 90.0 (13.7) | 88.3 (16.0) | 0.27 | 0.79 | 1.66 | −10.97 | 14.30 |
| Performance IQ (SD) | 85.8 (11.3) | 83.3 (7.67) | 0.66 | 0.52 | 2.52 | −5.90 | 10.46 |
| Full scale IQ (SD) | 87.0 (11.6) | 84.6 (11.4) | 0.52 | 0.61 | 2.38 | −7.11 | 11.87 |
| CPZ equivalents | |||||||
| Baseline (SD) | 1998 (2571) | 1185 (662) | 0.59a | 0.55 | |||
| Discharge (SD) | 1425 (1223) | 1914 (2179) | 0.36a | 0.72 | |||
| Days on placebo | 64.3 (51.8) | 49.7 (33.7) | 0.85 | 0.40 | 14.61 | −20.8 | 50.0 |
| Days from end of placebo phase to discharge | 331 (178) | 252 (197) | 1.07 | 0.29 | 79.10 | −73.0 | 231 |
a
Mann Whitney Z
b
Fisher’s Exact.
CI, confidence interval.